Lineage plasticity-mediated therapy resistance in prostate cancer

Alexandra Blee, Haojie Huang

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Therapy resistance is a significant challenge for prostate cancer treatment in clinic. Although targeted therapies such as androgen deprivation and androgen receptor (AR) inhibition are effective initially, tumor cells eventually evade these strategies through multiple mechanisms. Lineage reprogramming in response to hormone therapy represents a key mechanism that is increasingly observed. The studies in this area have revealed specific combinations of alterations present in adenocarcinomas that provide cells with the ability to transdifferentiate and perpetuate AR-independent tumor growth after androgen-based therapies. Interestingly, several master regulators have been identified that drive plasticity, some of which also play key roles during development and differentiation of the cell lineages in the normal prostate. Thus, further study of each AR-independent tumor type and understanding underlying mechanisms are warranted to develop combinational therapies that combat lineage plasticity in prostate cancer.

Original languageEnglish (US)
Pages (from-to)241-248
Number of pages8
JournalAsian Journal of Andrology
Issue number3
StatePublished - May 1 2019


  • Lineage plasticity
  • Neuroendocrine
  • Prostate cancer
  • Therapy resistance
  • Transdifferentiation

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Lineage plasticity-mediated therapy resistance in prostate cancer'. Together they form a unique fingerprint.

Cite this